Health News

Repros Therapeutics Inc. today announced that the Company has requested a Type B Meeting in order to review the Company’s Phase III protocols for Androxal in the treatment of secondary hypogonadism. Androxal is an oral drug that normalizes both testosterone and sperm levels.

Read more

Filed under: Pharmacy News
Tags: Drug, Pharmacy, sperm

Related posts

• Repros Therapeutics requests Type B Meeting to review Androxal Phase III protocols (0)
  Repros Therapeutics Inc. today announced that the Company has requested a Type B Meeting in order to review the Company's Phase III protocols for Androxal in the treatment of secondary hypogonadism. Androxal is an oral drug that normalizes both testosterone and sperm levels. Read more [tags] Pharmacy News [/tags]
  
  
• FDA grants Type B meeting to review Phase III pivotal efficacy protocols for Androxal (0)
  Repros Therapeutics Inc. today announced that the Company has been granted a Type B meeting to be held on November 8, 2010 with the Division of Reproductive and Urologic Products to review the Company's Phase III pivotal efficacy protocols for Androxal in the treatment of secondary hypogonadism. Androxal is an oral drug that normalizes both [...]
  
  
• Æterna Zentaris Zentaris requests EMA Scientific Advice for Phase 3 program with perifosine (0)
  Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that it has requested Scientific Advice from the European Medicines Agency (EMA) to assure the acceptability of the recently initiated Phase 3 programs for the development of its lead anticancer compound, perifosine, in its two lead indications, multiple myeloma [...]
  
  
• Æterna Zentaris commences perifosine Phase 3 registration trial (0)
  Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced the initiation of a Phase 3 registration clinical trial with perifosine (KRX-0401) ), the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, for the treatment of refractory advanced colorectal cancer. Read [...]
  
  
• ZyStor Therapeutics, Inc. Cleared To Begin Clinical Trial For Targeted Protein Therapeutic For The Treatment Of Pompe Disease (0)
  ZyStor Therapeutics, Inc., a biotechnology company developing a new class of targeted protein therapeutics for the treatment of Lysosomal Storage Diseases using the Company's proprietary Glycosylation Independent Lysosomal Targeting technology, announced that it has received clearance from the U. S. Food and Drug Administration to proceed into a clinical trial for its first drug candidate, [...]